Just to be clear:
My view is that the future of this company lies within the battery space. It's why I'm still here.
It's my view that the company is being diverted into expensive detours with diagnostics, with questionable results.
We still don't have a clear strategy about how the diagnostics space will deliver significant returns.
Instead we get tours of Japan. What was the outcome in terms of revenue?
Ann: IMRA Contract Additional Information, page-117
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
